CVR 43730967Private limited company (ApS)Fremstilling af farmaceutiske præparater (212000)AllerødFounded 22 Dec 2022
CVR holds no employment figures for this company.
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about Alteral Therapeutics ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexGross profit
-125.3K
DKK, annual report 2025
Result
+624K
DKK, annual report 2025
Equity
978.6K
DKK, annual report 2025
Wehnert Holding ApSCVR 43708554, 100% of capital and votes
Allan Traugott Wehnertsince 22 Dec 2022
Owners of 5% or more. CVR registers shares in bands, not exact figures.
CVR 43708554100% of capital and votesnotified 9 Oct 2023since 22 Dec 2022
CVR 4370595450% to under 66.7% of capital and votesnotified 9 Oct 202322 Dec 2022 to 9 Oct 2023
Ultimate controller
Holding in Wehnert Holding ApS, since 9 Dec 2022
Holding company
CVR 43708554Private limited company (ApS)
Holding in Alteral Therapeutics ApS, since 22 Dec 2022
This company
Alteral Therapeutics ApS
CVR 43730967
2 Danish companies.
CVR 4592934533.3% to under 50% of capital and votes
CVR 4448209610% to under 15% of capital and votes
Danish companies held at 5% or more, from the CVR owner register (ejerregister), and their holdings one level down. Foreign holdings are not in CVR.
CVR 3984231933.3% to under 50% of capital and votes8 Nov 2023 to 11 Nov 2024
CVR 4434884525% to under 33.3% of capital and votes2 Oct 2023 to 13 May 2024
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
Founded 22 Dec 2022.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
The company's own figures, in DKK, from the annual reports filed in XBRL.
2025, DKK: Operating profit -125.3K, Result for the year 624K
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2025, DKK: Total assets 1M, Equity 978.6K
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2023 | 2024 | 2025 |
|---|---|---|---|
| Gross profit | Not reported | Not reported | -125 |
| Operating profit | -79 | -6 | -125 |
| Result for the year | +294 | +20 | +624 |
| Equity | 334 | 355 | 979 |
| Total assets | 416 | 403 | 1,042 |
| Employees (average) | Not reported | Not reported | 0 |
| Credit metrics (Dandex calculations) | |||
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | ||
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may.
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
What Pro holds for Alteral Therapeutics ApS:
Have Pro? Sign in.
Amounts in DKK. Cash price is per DKK 1 of nominal capital, which a share split does not move.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| FoundingCashPaid in 80,000, cash price 2.00 | 2.00 | 80,000 | None | 40,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
Source: CVR, read 19 Nov 2026.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 19 Nov 2026.
5 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Ny adresse: Bakkevej 41, 3450 Allerød
Ny kommune: Allerød
Ny adresse: c/o Firm Management ApS, Dyrehavevej 3B, 2930 Klampenborg
Ny adresse: Mesterlodden 3A, 1., 2820 Gentofte
Ny kommune: Gentofte
Direktion:
Fratrådte:
Rasmus Christian Drewes Jensen, den 09.10.2023.
Tiltrådte:
Allan Traugott Wehnert, den 09.10.2023.
Direktion:
Fratrådte:
Allan Traugott Wehnert, den 21.08.2023.
Stiftelsesdato: 22.12.2022.
Virkningsdato: 22.12.2022.
Seneste vedtægtsdato: 22.12.2022.
Kapital:
kr. 40.000,00.
Kapitalklasser: Nej
Indbetalingsmåde: Indbetalt kontant kr. 40.000,00 til kurs 200,00, fuldt indbetalt.
Stiftere:
CVR-NR. 43705954 Drewes Jensen Holding ApS, Gustav Webersvej 31, 3520 Farum, den 22.12.2022, CVR-NR. 43708554 Wehnert Holding ApS, Bakkevej 41, 3450 Allerød, den 22.12.2022.
Direktion:
Rasmus Christian Drewes Jensen, den 22.12.2022, Allan Traugott Wehnert, den 22.12.2022.
Selskabet tegnes af direktionen i forening
Første regnskabsår:
22.12.2022 - 31.12.2023.
Regnskabsår:
01.01 - 31.12.
Formål:
Selskabets formål er at drive virksomhed med udvikling af lægemidler samt enhvervirksomhed i hermed stående forbindelse.
P-number 1028865429Bakkevej 41, 3450 Allerød